Beyond Borders: Exploring Interstitial Pneumonia with Autoimmune Features (IPAF) 


00:00:00.120 --> 00:00:01.440
OK, So hi everyone.

00:00:01.440 --> 00:00:06.501
Thank you for coming today attending the Rheumatology ILD Master Class and titled

00:00:06.501 --> 00:00:09.835
Beyond Borders:exploring interstitial pneumonia with

00:00:09.835 --> 00:00:14.280
auto immune features with Doctor Janet Pope and Doctor Daniel Marinescu.

00:00:14.560 --> 00:00:18.320
My name is Caroline Vo,
and I'm a rheumatologist and it's my

00:00:18.320 --> 00:00:23.396
pleasure today to moderate this evening's program and introduce you to tonight's

00:00:23.396 --> 00:00:23.960
speakers.

00:00:24.280 --> 00:00:28.120
So today we have Doctor Janet Pope, who is a rheumatologist.

00:00:28.320 --> 00:00:32.188
She's a Professor of Medicine in Rheumatology at the University of

00:00:32.188 --> 00:00:34.880
Western Ontario School of Medicine.

00:00:35.120 --> 00:00:40.060
She has published over 600 articles resulting in several research accolades

00:00:40.060 --> 00:00:45.195
and is also a passionate teacher educator, especially in rheumatoid arthritis,

00:00:45.195 --> 00:00:46.560
lupus and scleroderma.

00:00:47.000 --> 00:00:52.074
She currently Co-hosts some of the Around the Rheum podcasts after having been

00:00:52.074 --> 00:00:53.920
featured as a regular guest.

00:00:54.440 --> 00:00:59.857
Janet has a social media presence on Twitter
@janetbirdope where her

00:00:59.857 --> 00:01:05.492
#clinicalpearls have a reputation of teaching physical findings to more than

00:01:05.492 --> 00:01:06.720
20,000 followers.

00:01:09.320 --> 00:01:14.021
We alongside of Doctor Janet Pope,
we also have Doctor Daniel Marinescu who

00:01:14.021 --> 00:01:18.600
received his medical degree from McGill University and completed residency

00:01:18.600 --> 00:01:23.240
training in Internal Medicine and Respirology at the University of Toronto.

00:01:23.600 --> 00:01:28.552
He subsequently completed the two year fellowship in Interstitial Lung Disease

00:01:28.552 --> 00:01:32.815
and Master of Health Science at the University of British Columbia,

00:01:32.815 --> 00:01:36.640
Columbia with a focus in epidemiology and clinical research.

00:01:37.040 --> 00:01:42.472
He is a clinical Assistant Professor in
the Department of Medicine at UBC and A

00:01:42.472 --> 00:01:48.040
and a post Doctoral Research Fellow with the Center for Heart Lung Innovation.

00:01:48.080 --> 00:01:53.000
He works as a respirologist at Vancouver General Hospital at the Lung Center.

00:01:54.160 --> 00:01:54.520
Dr.

00:01:54.520 --> 00:01:59.582
Marinescu's research focuses on the morphology and diagnosis of ILD,

00:01:59.582 --> 00:02:05.305
with which he has studied at the Care-PF, the largest prospective registry of

00:02:05.305 --> 00:02:08.240
patient with fibrotic ILD in the world.

00:02:08.640 --> 00:02:12.997
He is interested in understanding how genetics contribute to ILD and its

00:02:12.997 --> 00:02:16.177
clinical outcomes which he hopes will be to

00:02:16.177 --> 00:02:20.240
improve diagnosis and personalized care in this challenging disease.

00:02:23.320 --> 00:02:26.560
So oh, sorry,
I forgot to change the slides.

00:02:27.040 --> 00:02:32.834
And so today before we start,
I have some few housekeeping items I have

00:02:32.834 --> 00:02:33.720
to mention.

00:02:34.880 --> 00:02:38.013
First,
we ask ask you to provide feedback at the

00:02:38.013 --> 00:02:43.194
conclusion of this event by completing the session evaluation that you will have

00:02:43.194 --> 00:02:46.520
the link at the end of the session in the chat box.

00:02:47.960 --> 00:02:53.276
We truly appreciate you taking the time to provide feedback as it helps

00:02:53.276 --> 00:02:58.393
to shape future programs and ensure that we are developing medical education

00:02:58.393 --> 00:03:03.377
programs that provides value. To ensure the best possible sound quality for

00:03:03.377 --> 00:03:04.640
everyone attending.

00:03:04.920 --> 00:03:07.880
Please note that all participants should be muted.

00:03:09.200 --> 00:03:13.063
If you have any question,
please write your question in the chat

00:03:13.063 --> 00:03:17.760
box and we will be able to ask those questions at the end of the presentation.

00:03:18.640 --> 00:03:25.129
Please note also that this presentation
is being recorded so people that won't be

00:03:25.129 --> 00:03:29.640
able to to attend this webinar could listen to it later on.

00:03:30.520 --> 00:03:34.766
And feel free to open your camera so it can be more interactive for the

00:03:34.766 --> 00:03:37.480
presentation and for the presentator as well.

00:03:40.320 --> 00:03:44.512
Before we start,
it is important to note that this program

00:03:44.512 --> 00:03:50.338
has received financial support that the faculty has received an honorary room for

00:03:50.338 --> 00:03:51.760
their participation.

00:03:52.600 --> 00:03:55.795
However,
the faculty is fully responsible

00:03:55.795 --> 00:04:00.789
for developing all content in this learning activity to achieve scientific

00:04:00.789 --> 00:04:03.120
integrity, objectivity and balance.

00:04:06.440 --> 00:04:10.080
So there there is no mitigated bias.

00:04:12.400 --> 00:04:14.400
Here are my faculty disclosure.

00:04:14.400 --> 00:04:21.717
I did have some some fees from BI as a presentator and also tonight as a

00:04:21.717 --> 00:04:22.720
moderator.

00:04:23.240 --> 00:04:28.960
And here are the faculty disclosures for Doctor Pope and for Doctor Marinescu.

00:04:29.600 --> 00:04:33.694
So without further ado,
here are the learning objective for

00:04:33.694 --> 00:04:34.240
tonight.

00:04:34.840 --> 00:04:38.868
We will be understanding the clinical manifestation of IPAF,

00:04:38.868 --> 00:04:43.677
discussing treatment options for IPAF and illustrating the importance of

00:04:43.677 --> 00:04:48.485
collaboration between astrologist and rheumatologists in managing

00:04:48.485 --> 00:04:49.720
patient with IPAF.

00:04:50.800 --> 00:04:55.963
So without further ado,
I will leave Doctor the presentators to

00:04:55.963 --> 00:04:57.920
start their presentation.

00:04:59.200 --> 00:04:59.600
Great.

00:04:59.840 --> 00:05:00.800
Thank you, Caroline.

00:05:00.800 --> 00:05:05.009
And we thought we would like to do something interesting,

00:05:05.009 --> 00:05:10.161
a case where maybe you know,
Rheum asked RASP and another case for
resps

00:05:10.161 --> 00:05:10.960
asked Rheum.

00:05:12.280 --> 00:05:15.440
So this one we're starting.

00:05:15.440 --> 00:05:17.720
And Daniel, am I starting or are you?

00:05:19.240 --> 00:05:21.600
Oh, feel free to feel free to start.

00:05:21.640 --> 00:05:21.840
Yeah.

00:05:22.360 --> 00:05:22.880
All right.

00:05:23.040 --> 00:05:24.840
Because we, we know these cases.

00:05:24.840 --> 00:05:25.880
We came up with them.

00:05:25.880 --> 00:05:30.480
So 67 year old man referred to rheumatology from the emergency room.

00:05:30.720 --> 00:05:36.368
So, 50 Pack/yr smoker quit two years ago because of the birth of his granddaughter,

00:05:36.368 --> 00:05:40.000
so it really motivated him with a little baby around.

00:05:40.240 --> 00:05:42.080
So he presented to the emergency room.

00:05:42.080 --> 00:05:43.540
He had an abnormal chest X-ray.

00:05:43.720 --> 00:05:46.400
You can see at the bases they are quite abnormal.

00:05:46.640 --> 00:05:50.816
He had some joint pain and why they did a rheumatoid factor in the emergency room

00:05:50.816 --> 00:05:53.720
is a little bit beyond me, but it was strongly positive.

00:05:54.080 --> 00:05:57.193
So the question they sent him to rheumatology is,

00:05:57.193 --> 00:05:59.000
is this rheumatoid arthritis?

00:05:59.360 --> 00:06:02.595
So obviously with the abnormal chest X-ray,

00:06:02.595 --> 00:06:08.478
somebody also quite appropriately ordered a
CT scan and you can see some changes

00:06:08.478 --> 00:06:08.920
there.

00:06:08.920 --> 00:06:12.080
And Daniel, can I ask just briefly, what, what would you say?

00:06:12.080 --> 00:06:15.160
I can tell it's abnormal as a rheumatologist, but what would you say?

00:06:15.840 --> 00:06:16.840
Yeah, sounds good.

00:06:17.800 --> 00:06:18.320
Happy to.

00:06:18.320 --> 00:06:20.711
So, so there's it's only one slice, but it,

00:06:20.711 --> 00:06:24.843
it seems like it would usually we're dealing with disease that's more basal

00:06:24.843 --> 00:06:28.485
predominant and it seems like this might be the case here as well,

00:06:28.485 --> 00:06:32.400
although it's hard to tell without kind of scrolling through all of it. 

00:06:33.200 --> 00:06:38.292
And we have mostly peripheral I would say both evidence of reticulation and

00:06:38.292 --> 00:06:42.620
fibrosis in the kind of the lines, extra lines that you see there,

00:06:42.620 --> 00:06:46.440
but also within it there's kind of an admixed ground glass.

00:06:46.640 --> 00:06:49.950
So both a bit of reticulation and a bit of ground glass,

00:06:49.950 --> 00:06:54.712
and there might even be some places where you can imagine - this isn't a great

00:06:54.712 --> 00:06:56.920
textbook example of subplural sparing.

00:06:56.920 --> 00:07:01.039
I, would never put it in a textbook, but you can with the eye of faith,

00:07:01.039 --> 00:07:02.320
maybe think about that.

00:07:02.320 --> 00:07:07.146
So a more difficult pattern,
but you would maybe air towards the side

00:07:07.146 --> 00:07:11.840
of something looking something towards NSIP if you had to put a label.

00:07:13.680 --> 00:07:17.713
So really quite helpful that we knew something obviously was going on in his

00:07:17.713 --> 00:07:18.040
lungs.

00:07:18.040 --> 00:07:23.480
So for many of you listening,
you know that rheumatoid arthritis is

00:07:23.480 --> 00:07:29.560
associated with ILD more a UIP pattern, but just about any pattern you could

00:07:29.560 --> 00:07:33.560
think of that's interstitial could be associated.

00:07:33.560 --> 00:07:36.560
So UIP, NSIP and some other patterns as well.

00:07:37.040 --> 00:07:40.233
It's relevant it,
it's more common than this,

00:07:40.233 --> 00:07:45.440
but it's about 7% of women and 8 to 10% of men will have relevant ILD.

00:07:45.520 --> 00:07:49.787
By that I mean progressive where we Co manage with our respirology colleagues

00:07:49.787 --> 00:07:52.960
and where it's going to cause big problems down the road.

00:07:53.360 --> 00:07:57.960
It is more common in positive RF possibly in men.

00:07:58.440 --> 00:08:01.840
There's always more women with it because 80% of RA is women.

00:08:02.080 --> 00:08:07.417
But the proportion of men having ILD is a bit higher, smokers, older age,

00:08:07.417 --> 00:08:11.240
longer disease duration, sometimes asthma, not usually.

00:08:11.240 --> 00:08:15.640
So there's some other associations and bad disease activity.

00:08:15.640 --> 00:08:20.350
So having gotten into damage like some of these hands here, you see a lot of damage,

00:08:20.350 --> 00:08:24.840
extra articular like nodules because of being
CR positive, more apt to get it.

00:08:25.120 --> 00:08:31.480
So bad disease activity equals higher chance of ILD over the years they have it.

00:08:31.720 --> 00:08:35.640
And to not forget,
there's a lot of lung manifestations of

00:08:35.640 --> 00:08:35.840
RA.

00:08:36.600 --> 00:08:42.112
So really from airway at the top with tracheal things and cartilage issues up

00:08:42.112 --> 00:08:48.190
to and included including you can get COP, you can get the interstitial lung disease,

00:08:48.190 --> 00:08:53.561
but you can have reactive airways and emphysema changes even in non-smokers

00:08:53.561 --> 00:08:56.317
with RA,
pleural disease and pulmonary

00:08:56.317 --> 00:08:58.720
hypertension to name some of many.

00:08:58.800 --> 00:09:02.405
So we have to think and we don't really put methotrexate lung on this list,

00:09:02.405 --> 00:09:05.535
just telling you they're right there because that's that happens,

00:09:05.535 --> 00:09:06.200
but very rare.

00:09:06.640 --> 00:09:12.040
The other weird thing is that this is 11, 000 patients from a Swedish registry.

00:09:12.040 --> 00:09:14.440
So these are population patients, patients with RA.

00:09:14.520 --> 00:09:18.600
They tried to verify the thing like the code that they really had RA.

00:09:18.600 --> 00:09:24.300
So this isn't a selected population and they compared to age, sex,

00:09:24.300 --> 00:09:31.362
match region controls and what they found was respiratory problems even five years

00:09:31.362 --> 00:09:38.680
before RA diagnosis were about 60% higher, so about a 1.6 odds ratio or hazard ratio.

00:09:38.880 --> 00:09:43.022
So even before you have your RA,
you might be getting lung problems that

00:09:43.022 --> 00:09:46.200
could be emphysema,
could be interstitial lung disease,

00:09:46.200 --> 00:09:47.960
could even be reactive airways.

00:09:48.120 --> 00:09:53.218
So we're expanding what we're understanding of RA as doing something

00:09:53.218 --> 00:09:57.281
bad to the lungs or conversely lungs precipitating RA,

00:09:57.281 --> 00:09:59.720
which is minimally controversial.

00:10:00.000 --> 00:10:04.032
This is a giant UK study of in the UK for no particular reason,

00:10:04.032 --> 00:10:08.821
they decided to look at thousands, hundreds of thousands of patients and do

00:10:08.821 --> 00:10:09.200
PFT's.

00:10:09.880 --> 00:10:12.358
So for no reason,
like a lot of them were done for no

00:10:12.358 --> 00:10:12.680
reason.

00:10:12.680 --> 00:10:15.760
And then comparing RA patients to general population. 

00:10:15.760 --> 00:10:19.440
So they have this big biobank where I think they were standardizing things.

00:10:19.640 --> 00:10:24.640
But anyway, over 300,000 patients RA, we're about 0.6%.

00:10:24.640 --> 00:10:26.440
So we think of RA as high as 1%.

00:10:26.440 --> 00:10:28.520
So 0.6% isn't so wrong.

00:10:28.760 --> 00:10:32.720
And again, 72% women,
it's about 80% in a lot of studies.

00:10:32.720 --> 00:10:39.320
So again quite accurate and about 3/4 being RF positive or a bit more.

00:10:39.640 --> 00:10:40.880
So what did they find?

00:10:40.880 --> 00:10:45.093
They found restrictive lung disease is more common in the RA patients than the

00:10:45.093 --> 00:10:48.560
general's very match population because it was a giant data set.

00:10:49.360 --> 00:10:55.778
So mild restrictive about a 1.34 odds,
a moderate about the same idea and severe

00:10:55.778 --> 00:10:57.680
about two fold increase.

00:10:57.920 --> 00:10:59.240
OK, we kind of know that.

00:10:59.240 --> 00:11:03.240
But obstructive was also increased, not mild but moderate or severe.

00:11:03.520 --> 00:11:06.930
And in other studies, including from BC database,

00:11:06.930 --> 00:11:11.704
the billing database, the BC,
they found that emphysema was increased

00:11:11.704 --> 00:11:16.547
in RA non-smokers about five times more than the general population of

00:11:16.547 --> 00:11:20.640
non-smokers even one to two years before they had their RA.

00:11:21.000 --> 00:11:24.240
So there's a lot we don't know about obstructive changes too.

00:11:24.640 --> 00:11:28.316
And the prevalence of ILD, you can see here it can vary,

00:11:28.316 --> 00:11:32.250
but in general and rheumatoid it's about 10% of rheumatoids,

00:11:32.250 --> 00:11:37.087
it's more but 10% being clinically relevant that we get our respirologists

00:11:37.087 --> 00:11:41.473
involved Scleroderma one in,
three to one in and you know to even 1

00:11:41.473 --> 00:11:45.472
and 2 will have ILD,
it's clinically relevant in at least 15% of

00:11:45.472 --> 00:11:46.440
those patients.

00:11:46.640 --> 00:11:49.040
Myositis, you can see the various odds.

00:11:49.320 --> 00:11:52.845
Lupus not very common, undifferentiated connective tissue

00:11:52.845 --> 00:11:54.000
disease, who knows.

00:11:54.160 --> 00:11:57.609
But if they look like Scleroderma-like they have a Scleroderma risk,

00:11:57.609 --> 00:12:00.320
if they look myositis-like they have a myositis risk.

00:12:00.960 --> 00:12:02.200
So we're back to the guy.

00:12:02.200 --> 00:12:05.737
So our guy is a smoker,
strongly positive RF and he had joint

00:12:05.737 --> 00:12:06.080
pains.

00:12:06.280 --> 00:12:10.932
He had this ILD picture certainly on chest X-ray and confirmed at least on

00:12:10.932 --> 00:12:12.640
the view we showed you on CT.

00:12:13.120 --> 00:12:17.415
So interestingly,
he's over 60 and he's had Raynaud's the

00:12:17.415 --> 00:12:18.600
last four years.

00:12:18.600 --> 00:12:21.080
So our antenna and rheumatology go up.

00:12:21.240 --> 00:12:25.985
If you get Raynaud's over the age of 50, we always wonder is there a secondary

00:12:25.985 --> 00:12:26.680
association?

00:12:26.880 --> 00:12:29.610
Whereas if you get it when you're 32, that's really common,

00:12:29.610 --> 00:12:31.840
and if you get it as a teen, it's really common.

00:12:32.560 --> 00:12:34.640
So no symptoms of inflammatory arthritis.

00:12:34.880 --> 00:12:35.840
His joint pains.

00:12:35.840 --> 00:12:38.760
He had worked in construction and he had what we call worker hand.

00:12:38.920 --> 00:12:44.736
He had osteoarthritis in his hands and he worked in construction just to know until

00:12:44.736 --> 00:12:45.360
retiring.

00:12:45.360 --> 00:12:47.160
And heaven knows what that means.

00:12:47.160 --> 00:12:52.438
On exposure of stuff that you're digging up and jackhammering and silica dust,

00:12:52.438 --> 00:12:53.040
etcetera.

00:12:53.280 --> 00:12:55.320
No past chest X-rays or PFTs.

00:12:55.520 --> 00:12:57.976
Well,
except for mild high blood pressure on

00:12:57.976 --> 00:12:59.560
treatment, no worrisome meds.

00:12:59.560 --> 00:13:03.840
So no nitrofurantoin or chemo with bleomycin or anything like that.

00:13:04.680 --> 00:13:08.480
He maybe had frequent pneumonia as a baby, but he's grasping at straws.

00:13:08.480 --> 00:13:13.554
When he was asked the question,
his aunt had RA or maybe OA and half of

00:13:13.554 --> 00:13:19.262
self report of RA and half of
family history report of RA isn't. Half is,

00:13:19.262 --> 00:13:20.320
but half isn't.

00:13:20.440 --> 00:13:23.904
So they double the the prevalence of RA if they make it up by saying yeah,

00:13:23.904 --> 00:13:27.000
"my aunt was like crippled up" and it could
have been a roast of OA.

00:13:27.520 --> 00:13:29.527
So we look at him,
no inflammatory arthritis,

00:13:29.527 --> 00:13:30.880
but he did have OA of his hand.

00:13:30.960 --> 00:13:36.352
He had bilateral basal crackles to the mid lungs bilaterally posteriorly normal

00:13:36.352 --> 00:13:38.240
vitals strongly positive RF.

00:13:38.240 --> 00:13:39.040
We didn't repeat it.

00:13:39.040 --> 00:13:41.440
We were just recording what he already had.

00:13:41.600 --> 00:13:47.180
Anti CCP was done because it might be relevant to this case with the RF because

00:13:47.180 --> 00:13:51.080
I'm just telling you that lungs sometimes predate the RA.

00:13:51.240 --> 00:13:55.954
So negative, anti CCP, ANA, moderate positive, interestingly,

00:13:55.954 --> 00:14:02.320
and so in ENA was done, the extractable nuclear antigens, and he was Ro positive.

00:14:02.520 --> 00:14:11.880
So if I was going to highlight Renaud's RF, Ro and ANA and having this ILD.

00:14:12.960 --> 00:14:14.440
So let's put the poll up.

00:14:14.440 --> 00:14:15.720
So what do you think this patient has?

00:14:15.720 --> 00:14:20.598
We can pull up right now. RA, UIP, IPAF or none of the above because I'm not really

00:14:20.598 --> 00:14:23.378
sure,
but let's vote and see what people say

00:14:23.378 --> 00:14:26.465
and we'll leave it up for maybe another few

00:14:26.465 --> 00:14:26.960
seconds.

00:14:28.040 --> 00:14:28.160
Yeah.

00:14:28.240 --> 00:14:29.880
So we got lots of people voting.

00:14:29.880 --> 00:14:35.200
And I mean, you know,
the title of our lecture is tonight.

00:14:35.200 --> 00:14:37.160
So OK, we'll end the poll.

00:14:37.160 --> 00:14:40.480
So 70% said IPAF and 10 and 10

00:14:40.480 --> 00:14:45.880
I thought it would be kind of split somehow. It says "failed to show the poll"

00:14:45.880 --> 00:14:48.000
Sorry I'm sharing but I didn't share.

00:14:48.120 --> 00:14:55.720
So 70% IPAF and about 10% of of UIP or RA and some people did a cop out.

00:14:55.720 --> 00:14:56.320
It's none of it.

00:14:56.320 --> 00:15:00.240
I think it's his,
his occupational exposure from silica

00:15:00.240 --> 00:15:03.600
dust, which you know, increases lots of things.

00:15:03.600 --> 00:15:06.120
So we, we might go there at some point.

00:15:06.360 --> 00:15:08.120
So oops, sorry.

00:15:08.400 --> 00:15:09.560
So just going back.

00:15:09.560 --> 00:15:13.160
So my questions to respirology for Daniel to help.

00:15:13.440 --> 00:15:16.353
So you know,
is this IPF if we get more cuts,

00:15:16.353 --> 00:15:18.760
do we have some honeycombing in there?

00:15:18.760 --> 00:15:20.360
Do I need it to be UIP?

00:15:20.360 --> 00:15:23.240
Well, I think of IPF having UIP of course.

00:15:23.480 --> 00:15:26.400
Is it RA-ILD or do you guys think it's IPAF?

00:15:26.680 --> 00:15:29.400
And then what, what should we follow?

00:15:29.400 --> 00:15:32.960
Like this guy did come to the emergency emergency room with symptoms.

00:15:32.960 --> 00:15:36.520
So do we follow his PFTs and HRCT?

00:15:36.520 --> 00:15:41.480
Do we just need PFTs because we know his CT is already not normal and how often?

00:15:41.480 --> 00:15:44.956
So Daniel,
I'm going to shift here the slide and

00:15:44.956 --> 00:15:50.073
send it to you to tell me what to do with this guy and to tell me what he has

00:15:50.073 --> 00:15:51.320
sounds good.

00:15:52.520 --> 00:15:55.328
We might not be much further ahead, but, but I'll give it a,

00:15:55.328 --> 00:15:56.480
I'll give it a shot here.

00:15:57.400 --> 00:16:00.995
And I,
I like to think about it in terms of ILD 

00:16:00.995 --> 00:16:06.389
and especially ILD when there's,
we rely a lot in terms of diagnosis on

00:16:06.389 --> 00:16:10.360
the pattern and the way things look like on imaging.

00:16:11.040 --> 00:16:14.380
And typically I think of when I think of, for example, an,

00:16:14.380 --> 00:16:17.381
an NSIP kind of picture or a slam dunk NSIP picture,

00:16:17.381 --> 00:16:21.627
I like to think of things that are
clearly very associated with CTD on one

00:16:21.627 --> 00:16:22.759
end of the spectrum.

00:16:22.800 --> 00:16:27.040
And then you have NSIP, for example, that's just sitting there for no reason.

00:16:27.280 --> 00:16:30.680
And it's sort of what we call, quote un-quote, idiopathic.

00:16:30.680 --> 00:16:35.240
And anything is idiopathic if you don't understand it or if you don't look hard

00:16:35.240 --> 00:16:35.640
enough.

00:16:36.480 --> 00:16:39.287
And so if you go forward a couple of times, sorry,

00:16:39.287 --> 00:16:42.040
I have a couple of animations here on this slide.

00:16:43.400 --> 00:16:44.000
Sorry.

00:16:44.640 --> 00:16:47.520
Yeah, OK, let's try it again.

00:16:47.520 --> 00:16:51.320
Sometimes my clicking there we go others, yeah, yeah.

00:16:51.600 --> 00:16:55.782
So on one end of the spectrum if you have a clear underlying CTD,

00:16:55.782 --> 00:16:58.000
we'll we'll label that as a CTD-ILD.

00:16:58.200 --> 00:17:02.991
On the other end of the spectrum,
if you have for example a UIP pattern on

00:17:02.991 --> 00:17:08.357
imaging and we can't find a reason for it and especially if you're an older male ex

00:17:08.357 --> 00:17:11.360
smoker,
we've come up with a specific name for

00:17:11.360 --> 00:17:11.680
that.
00:17:11.960 --> 00:17:14.680
And the specific name for that is is IPF now.

00:17:15.000 --> 00:17:19.619
But if you have NSIP, for example, and you have no idea why it's there,

00:17:19.619 --> 00:17:23.340
you could just as easily label that with idiopathic NSIP,

00:17:23.340 --> 00:17:27.959
which is another diagnostic label that we have in our bucket of labels.

00:17:28.440 --> 00:17:31.200
But who's to say exactly what that is?

00:17:31.680 --> 00:17:36.974
And so somewhere in the middle of this is, is what has been defined as IPAF,

00:17:36.974 --> 00:17:40.571
where you have some kind of flavour of autoimmunity,

00:17:40.571 --> 00:17:45.798
some flavour of CTD features and maybe even some morphologic features on

00:17:45.798 --> 00:17:49.531
on CT scan or pathology to suggest something CTD like,

00:17:49.531 --> 00:17:53.400
but not quite enough to get us there to a bonafide CTD.

00:17:53.760 --> 00:17:58.393
And this this is something that was really developed as a research statement

00:17:58.393 --> 00:18:03.207
and probably mostly to get our foot in the door in order to be able to assign a

00:18:03.207 --> 00:18:07.600
label to this thing and then be able to study it and see where it falls.

00:18:07.600 --> 00:18:09.880
If it is it more similar to CTD to not?

00:18:09.880 --> 00:18:11.000
Is it a different entity?

00:18:11.240 --> 00:18:14.330
And, and we don't know yet, but starting with a definition is,

00:18:14.330 --> 00:18:18.156
is naming something is the first thing you always have to do before you to

00:18:18.156 --> 00:18:19.040
start to study it.

00:18:21.360 --> 00:18:26.878
And so IPAF interstitial pneumonia with autoimmune features, it's really the,

00:18:26.878 --> 00:18:32.326
the classification for it is that you have to have an interstitial pneumonia,

00:18:32.326 --> 00:18:35.400
you have to exclude alternative etiologies.

00:18:35.680 --> 00:18:39.561
And two and three on this slide are kind of the same thing because you don't meet

00:18:39.561 --> 00:18:40.840
criteria for a defined CTD.

00:18:40.840 --> 00:18:44.960
So that essentially kind of excludes that CTD-ILD nature of it.

00:18:45.760 --> 00:18:48.305
And then if you have all of these
features,

00:18:48.305 --> 00:18:52.644
then you look at 3 domains and you ideally want to have kind of two out of

00:18:52.644 --> 00:18:56.000
three of these clinical serologic or morphologic domains.

00:18:56.000 --> 00:18:57.840
And we'll talk a little bit about them.

00:18:58.760 --> 00:19:02.631
So on next slide,
here are some of the clinical,

00:19:02.631 --> 00:19:08.320
all the features I should say,
and you guys know this better than I do.

00:19:08.320 --> 00:19:13.062
And we as respirologists rely a ton on rheumatologists for looking at those

00:19:13.062 --> 00:19:18.054
clinical features and as well as perhaps annoyingly interpreting some serologic

00:19:18.054 --> 00:19:20.800
features when we send off a myositis panel.

00:19:20.800 --> 00:19:23.385
And,
and we might not have the best idea of

00:19:23.385 --> 00:19:27.439
what this means if you know,
X or Y is positive in the setting of no

00:19:27.439 --> 00:19:29.320
other kind of clinical symptoms.

00:19:30.040 --> 00:19:32.822
But all this is to highlight Raynaud's is a

00:19:32.822 --> 00:19:37.251
a pretty common one that shows up that would meet the criteria for a clinical

00:19:37.251 --> 00:19:38.160
feature up here.

00:19:39.120 --> 00:19:44.472
And then in terms of morphologic features, which is where I'd like to spend a little

00:19:44.472 --> 00:19:49.258
bit more of my time on and really on radiology because histopathology we're

00:19:49.258 --> 00:19:53.603
doing biopsies less and less,
but the morphologic features that were

00:19:53.603 --> 00:19:58.200
defined for this entity are really NSIP, OP or an overlap between the two.

00:19:58.960 --> 00:20:02.583
And you can look at that and you can say, hey, why isn't,

00:20:02.583 --> 00:20:05.520
why aren't other morphologic patterns on here?

00:20:05.720 --> 00:20:08.120
If you have UIP,
does this not make it IPAF?

00:20:08.120 --> 00:20:12.233
If you have a flavour of autoimmunity? if you have an airway centric pattern,

00:20:12.233 --> 00:20:14.080
does it not make it IPAF anymore?

00:20:14.840 --> 00:20:15.280
And.

00:20:16.120 --> 00:20:17.880
I,
I don't know what the right answer is to

00:20:17.880 --> 00:20:18.080
that.

00:20:18.080 --> 00:20:23.053
The reason why we define this using anchoring predominantly in an NSIP or an

00:20:23.053 --> 00:20:27.962
OP pattern is because these are the patterns that we know and seem to occur

00:20:27.962 --> 00:20:33.000
most commonly in some of the best studied ILD, like Scleroderma, for example.

00:20:33.640 --> 00:20:36.955
And, and because of that when we see NSIP,

00:20:36.955 --> 00:20:41.609
we tend to anchor towards, oh,
could there be an autoimmune disease here

00:20:41.609 --> 00:20:42.120
as well?

00:20:42.840 --> 00:20:45.760
And that's really the reason why it's on this list.

00:20:45.760 --> 00:20:48.280
And you fHP or airway centric disease isn't.

00:20:48.640 --> 00:20:52.958
So if you, if we go forward a little bit, just one, one comment went well,

00:20:52.958 --> 00:20:55.320
there's a question from the audience too.

00:20:55.320 --> 00:20:57.120
Two people are thinking the same way.

00:20:57.320 --> 00:21:01.520
And then before that just would it for the rest of the rheumatologist.

00:21:01.520 --> 00:21:03.560
What does OP stand for?

00:21:03.560 --> 00:21:04.960
For us, it's osteoporosis.

00:21:04.960 --> 00:21:07.360
So we know it's not fair enough.

00:21:07.360 --> 00:21:07.920
Fair enough.

00:21:07.920 --> 00:21:10.065
No,
you wouldn't want me diagnosing

00:21:10.065 --> 00:21:10.840
osteoporosis.

00:21:11.480 --> 00:21:13.360
OP would be organizing pneumonia.

00:21:14.240 --> 00:21:17.400
NSIP here would be non specific interstitial pneumonia.

00:21:18.280 --> 00:21:22.676
The non specific interstitial pneumonia is a little bit of a misnomer in the

00:21:22.676 --> 00:21:27.243
sense that it it tends to have a fairly specific look on it on radiology and

00:21:27.243 --> 00:21:30.840
in terms of being basal predominant, having more ground glass.

00:21:30.840 --> 00:21:34.729
And in about 1/4 of cases,
there's this entity of subpleural sparing

00:21:34.729 --> 00:21:39.240
where just along the edge of the pleura, the disease gets milder or disappears.

00:21:39.720 --> 00:21:42.893
And,
and that really gives you a sense of what

00:21:42.893 --> 00:21:48.091
we classically define as NSIP. Organizing pneumonia is really just defined by

00:21:48.091 --> 00:21:53.019
consolidation and ground glass and, and really what's called perilobular

00:21:53.019 --> 00:21:53.560
sparing.

00:21:53.560 --> 00:21:57.806
So you'll see 1 little lobule of the lung that looks normal and right beside it,

00:21:57.806 --> 00:22:00.480
another one that's kind of consolidated and white.

00:22:01.120 --> 00:22:04.720
And, and that's what radiologists, that's, that's the whole magic of OP.

00:22:05.360 --> 00:22:09.424
That's what radiologists look to see to say, "hey, this,

00:22:09.424 --> 00:22:14.723
looks like OP" and for for the older rheumatologists in the gang, COP

00:22:14.723 --> 00:22:20.240
cryptogenic organizing pneumonitis or pneumonia; formerly known as BOOP.

00:22:20.440 --> 00:22:21.520
That's what we're talking about.

00:22:21.720 --> 00:22:22.920
Just to know.

00:22:23.080 --> 00:22:26.150
So the audience is kind of implying, well, you know,

00:22:26.150 --> 00:22:28.120
this guy had Reynolds older onset.

00:22:28.120 --> 00:22:30.400
Did he not like what about myositis panel?

00:22:30.400 --> 00:22:33.520
So the question is, so I didn't order.

00:22:33.520 --> 00:22:36.450
This is a fake case,
but I've had people like this is based on

00:22:36.450 --> 00:22:37.520
real people by the way.

00:22:37.520 --> 00:22:44.733
But I didn't order myositis panel because he meets IPAF anyway and he his power

00:22:44.733 --> 00:22:46.960
was strong like this guy.

00:22:46.960 --> 00:22:52.681
Actually he was a construction worker and he had maintained his muscle strength so

00:22:52.681 --> 00:22:54.680
there was no mechanic's hand.

00:22:55.000 --> 00:22:59.640
Stay tuned for more cases maybe,
but we didn't, like his CK wasn't done.

00:22:59.640 --> 00:23:02.990
His power was fine and probably eventually his CK was done,

00:23:02.990 --> 00:23:07.123
but it probably wouldn't have changed what we were thinking at this point

00:23:07.123 --> 00:23:11.200
because clinically he did not not have inflammatory myositis.

00:23:11.480 --> 00:23:13.912
And you know,
they're kind of pesky antibodies,

00:23:13.912 --> 00:23:17.866
these myositis panel because I think every week there's a new one and I don't

00:23:17.866 --> 00:23:19.639
know how to interpret lots of them. 

00:23:19.880 --> 00:23:22.609
So I didn't,
I didn't think it would matter with the

00:23:22.609 --> 00:23:26.730
strongly positive his ANA meets it and his RF meets it and we didn't clinically

00:23:26.730 --> 00:23:27.399
see myositis.

00:23:27.400 --> 00:23:28.600
But it's a really good question.

00:23:28.800 --> 00:23:32.630
And Daniel, if you had said,
can you guys look harder to tell us what

00:23:32.630 --> 00:23:35.311
he really has because it might affect treatment,

00:23:35.311 --> 00:23:39.360
then we would have probably gone on to do like say a double stranded DNA.

00:23:39.520 --> 00:23:42.360
But we didn't think he had lupus, a myositis panel, etcetera.

00:23:42.560 --> 00:23:45.080
But it's good 2 people in the audience picked it up right away.

00:23:45.080 --> 00:23:46.840
So good for them.

00:23:47.000 --> 00:23:50.371
But if you like, we don't usually witch hunt too much,

00:23:50.371 --> 00:23:53.120
but we will do it because it could affect
treatment.

00:23:53.280 --> 00:23:56.705
And now that we prioritize different treatments and different diseases,

00:23:56.705 --> 00:23:57.800
it might affect it too.

00:23:58.840 --> 00:24:00.120
So thanks for that.

00:24:00.120 --> 00:24:03.000
I'm just trying to move on somewhere.

00:24:03.240 --> 00:24:05.880
My cursor is Oh yeah, sorry.

00:24:06.280 --> 00:24:07.040
Yes, yeah.

00:24:07.400 --> 00:24:11.212
So this is as I was saying,
why not other patterns here and just

00:24:11.212 --> 00:24:15.611
because we have more experience with the prevalence of NSIP and autoimmune

00:24:15.611 --> 00:24:17.840
flavored or CTD-ILD kind of phenotypes.

00:24:18.120 --> 00:24:21.840
If you go over to the next slide, we'll see a little bit why.

00:24:21.840 --> 00:24:27.689
So this was part of a meta analysis that looked at CTD-ILD specifically and looked

00:24:27.689 --> 00:24:33.040
at different patterns that come out in
these different subtypes of of CTD.

00:24:33.680 --> 00:24:37.960
And you can see in rheumatoid arthritis about 50/50 be between UIP and NSIP.

00:24:38.920 --> 00:24:41.775
In Scleroderma,
the majority of cases are going to be

00:24:41.775 --> 00:24:42.040
NSIP.

00:24:42.840 --> 00:24:46.353
In myositis,
you'll see this overlap between NSIP and

00:24:46.353 --> 00:24:47.720
organizing pneumonia.

00:24:48.360 --> 00:24:52.725
So really Scleroderma,
which really forms the crux of our

00:24:52.725 --> 00:24:56.037
evidence in CTD-ILD and myositis especially,

00:24:56.037 --> 00:25:01.833
it's more of this kind of what we think is more inflammatory NSIP kind of OP
00:25:01.833 --> 00:25:02.360
flavor.

00:25:03.080 --> 00:25:05.600
And then you have a, a smattering of, of other things.

00:25:05.600 --> 00:25:10.394
But really our confidence in something that's autoimmune flavoured is,

00:25:10.394 --> 00:25:14.379
is geared a lot in NSIP,
which is why when this statement,

00:25:14.379 --> 00:25:18.026
this research statement defining IPAF was developed,

00:25:18.026 --> 00:25:22.686
they really wanted kind of to see NSIP from a morphologic domain to,

00:25:22.686 --> 00:25:25.319
to give it points towards autoimmunity.

00:25:25.600 --> 00:25:29.106
But as as I said before, I would argue, does that mean that if you have a UIP

00:25:29.106 --> 00:25:31.399
pattern it,
it shouldn't qualify and you shouldn't

00:25:31.399 --> 00:25:34.680
treat it that way if you have a,
a positive RF and kind of the same case

00:25:34.680 --> 00:25:35.400
in front of you?

00:25:35.840 --> 00:25:38.570
I don't know, I would err towards the side of saying no

00:25:38.570 --> 00:25:41.080
that still probably we should think about that as IPAF.

00:25:41.800 --> 00:25:45.404
And maybe I'm a little bit ahead of the game in that thinking,

00:25:45.404 --> 00:25:49.696
but our research statement and our research definition hasn't quite caught

00:25:49.696 --> 00:25:50.440
up with that.

00:25:51.400 --> 00:25:54.160
If we go forward one more slide here.

00:25:56.080 --> 00:25:56.240
Yeah.

00:25:56.600 --> 00:26:00.473
So this is some of our own data from from the Canadian Registry for Pulmonary

00:26:00.473 --> 00:26:00.920
Fibrosis.

00:26:00.920 --> 00:26:02.840
And there's,
there's a lot of stuff on this slide.

00:26:02.840 --> 00:26:07.847
But basically all of this is to say we we looked at about 1600 patients where we

00:26:07.847 --> 00:26:12.854
had a chest radiologist go through their imaging at presentation and really hone

00:26:12.854 --> 00:26:16.439
down on what the pattern of their imaging is at the time.

00:26:16.840 --> 00:26:22.254
And contrary to the last slide where we really looked at UIP and NSIP and OP,

00:26:22.254 --> 00:26:27.600
there's sort of been a new kind of pattern on the block that's been defined.

00:26:27.600 --> 00:26:30.209
It it, it's not actually new, but just the,

00:26:30.209 --> 00:26:35.012
the word for it or the definition for it came with a new guideline that that was

00:26:35.012 --> 00:26:36.080
published in 2021.

00:26:36.320 --> 00:26:41.015
And that's what we call an FHP like pattern and a fibrotic hypersensitivity

00:26:41.015 --> 00:26:42.560
pneumonitis like pattern.

00:26:43.080 --> 00:26:46.680
All of that is to say that pattern is supposed to be more airway centric.

00:26:46.920 --> 00:26:48.880
So you're supposed to have more airways disease.

00:26:48.880 --> 00:26:53.080
So UIP had its kind of set of basal predominant fibrosis.

00:26:53.400 --> 00:26:56.436
NSIP looked a little bit more ground glassy,

00:26:56.436 --> 00:27:01.835
but still basal predominant and this FHP or airway centric pattern really shows

00:27:01.835 --> 00:27:03.320
areas of air trapping.

00:27:03.320 --> 00:27:07.643
And as we saw from the previous slide, a lot of these CTD patients can present

00:27:07.643 --> 00:27:11.966
with obstructive airways disease as well and we don't understand that quite as

00:27:11.966 --> 00:27:12.240
well.

00:27:12.960 --> 00:27:16.494
But now again we're defining more and segmenting more and more of these

00:27:16.494 --> 00:27:18.680
patterns to try to get a better understanding.

00:27:18.960 --> 00:27:24.229
And I've included this slide just to say that there is a ton of patients with

00:27:24.229 --> 00:27:29.499
CTD-ILD or with IPAF that you see in the green that have not only typical UIP

00:27:29.499 --> 00:27:33.890
patterns that you see in the first kind of two bars on the left,

00:27:33.890 --> 00:27:39.025
but also in the last two second to last two bars on the right where it says

00:27:39.025 --> 00:27:41.119
compatible FHP and typical FHP.

00:27:41.120 --> 00:27:45.439
So these are airway centered type of patterns where you see gas trapping and

00:27:45.439 --> 00:27:49.926
mosaic attenuation and there's a ton of patients that present with this kind of

00:27:49.926 --> 00:27:50.880
appearance on CT.

00:27:51.520 --> 00:27:55.974
So all of this is to bring it back to the point that, you know, is NSIP and OP,

00:27:55.974 --> 00:27:59.760
are those the only patterns that are going to lead us towards IPAF?

00:28:00.000 --> 00:28:04.636
If you go by the strict letter of the law of what was published in, you know,

00:28:04.636 --> 00:28:08.481
in 2015, then yes,
you would have to say it has to be only

00:28:08.481 --> 00:28:09.160
NSIP and OP.

00:28:09.560 --> 00:28:14.134
And I would say that more and more we're finding out that CTD-ILD can present in

00:28:14.134 --> 00:28:17.964
other ways as well with UIP, especially in RA or with airway centric

00:28:17.964 --> 00:28:19.680
disease and a bunch of CTD-ILD.

00:28:19.680 --> 00:28:23.322
And maybe that should also qualify you as
IPAF or at least in my mind,

00:28:23.322 --> 00:28:26.560
I still think of it as being potentially compatible with IPAF.

00:28:27.680 --> 00:28:30.840
So just one question before we move on and a comment.

00:28:30.840 --> 00:28:33.960
I think our patients,
our general population is aging.

00:28:33.960 --> 00:28:37.000
So people are getting older with some of these diagnosis.

00:28:37.200 --> 00:28:42.679
We think of IPF as older guys in general, but even our connective tissue disease

00:28:42.679 --> 00:28:47.280
age of onset is going up overtime as our general population is too.

00:28:47.520 --> 00:28:51.177
And I think we're seeing more mixed bags because they might have some old things

00:28:51.177 --> 00:28:52.080
that we didn't, like

00:28:52.080 --> 00:28:55.790
no one did a chest X-ray when something else was going on and we're seeing

00:28:55.790 --> 00:28:58.213
restrictive,
obstructive and then and trying to,

00:28:58.213 --> 00:29:00.440
you know,
who treats what and what do we do?

00:29:00.520 --> 00:29:01.680
So just a comment.

00:29:01.680 --> 00:29:04.960
I agree it's quite,
it's getting more complicated.

00:29:05.160 --> 00:29:09.708
We want a really good radiologist and we want the respirologist like now every

00:29:09.708 --> 00:29:14.544
respirologist certainly that does general resp and then specialty rest knows how to

00:29:14.544 --> 00:29:15.120
treat IPF.

00:29:15.120 --> 00:29:18.097
So that helps us for them to say it's not that or it is,

00:29:18.097 --> 00:29:21.859
but there's a question that came up and I think it's good in this case,

00:29:21.859 --> 00:29:24.680
it'll probably be relevant to the other case as well.

00:29:24.880 --> 00:29:31.146
So if someone has an RNP, sometimes our ENA just says "up to

00:29:31.146 --> 00:29:34.280
0.8 is negative, 1 is positive, 2 is more positive.

00:29:34.280 --> 00:29:35.440
But we they don't go up.

00:29:35.440 --> 00:29:37.240
We don't know that it's strongly positive.

00:29:37.240 --> 00:29:39.040
Like they don't go to 16 or anything.

00:29:39.240 --> 00:29:44.960
So some of these ENAs
don't tell us how positive it is.

00:29:44.960 --> 00:29:49.660
And a question is, you know,
if I have a person with an RNP that's

00:29:49.660 --> 00:29:52.280
a 2 and less than 0.8 is a negative.

00:29:52.280 --> 00:29:56.297
So it's a bit, it's like double, maybe, maybe double to triple the upper limit of

00:29:56.297 --> 00:29:56.640
normal.

00:29:57.160 --> 00:30:00.556
Do we, you know,
are we supposed to tell you the RNP is

00:30:00.556 --> 00:30:02.800
irrelevant if we can't find anything?

00:30:02.920 --> 00:30:06.295
Or are we supposed to just say you want us to use a drug and we'll do it because

00:30:06.295 --> 00:30:07.920
we know how to get the drugs sometimes?

00:30:08.120 --> 00:30:10.080
So it is, it's a valid question.

00:30:10.080 --> 00:30:12.645
And Daniel,
I don't know if you have an easy answer

00:30:12.645 --> 00:30:13.040
to that.

00:30:14.520 --> 00:30:17.954
I would this,
this starts to get on that spectrum of

00:30:17.954 --> 00:30:19.640
kind of of of probability.

00:30:19.640 --> 00:30:24.696
And I would say that the same way I I've just talked about kind of the morphology,

00:30:24.696 --> 00:30:29.022
the that NSIP-OP pattern being more indicative or perhaps more strongly

00:30:29.022 --> 00:30:32.800
anchored in our minds to something with an autoimmune flavor.

00:30:33.000 --> 00:30:38.248
So if you have a borderline serology like that with something that's really NSIP-OP

00:30:38.248 --> 00:30:41.283
looking, I'm more leaning towards, for example,

00:30:41.283 --> 00:30:44.382
more often calling that IPAF and saying, yeah,

00:30:44.382 --> 00:30:49.251
that probably is significant If if you have something that looks not like an

00:30:49.251 --> 00:30:53.235
NSIP-OP, if you have, you know, UIP and an older male smoker

00:30:53.235 --> 00:30:56.460
otherwise, and really nothing else to speak up for

00:30:56.460 --> 00:31:00.824
CTD except that that RNP, I might be leaning more towards calling that

00:31:00.824 --> 00:31:03.479
something different and ignoring that.

00:31:04.040 --> 00:31:10.407
So that the the other features in this table basically kind of point me towards

00:31:10.407 --> 00:31:11.920
one way or another.

00:31:12.360 --> 00:31:16.632
If the other features in the clinical and morphologic domains are are strongly

00:31:16.632 --> 00:31:20.040
rooting me towards IPAF,
I'm comfortable going towards there.

00:31:20.240 --> 00:31:23.472
If if they don't,
then then maybe it's easier to ignore

00:31:23.472 --> 00:31:24.800
that serologic feature.

00:31:26.560 --> 00:31:30.120
So it's putting all our our brains together and trying to decide.

00:31:30.120 --> 00:31:36.720
So Reynaud's strongly positive RF, ANA
and this Ro, he's an NSIP.

00:31:37.840 --> 00:31:39.800
So we couldn't call him RA.

00:31:40.320 --> 00:31:42.400
And we sent them to Daniel.

00:31:42.400 --> 00:31:45.280
And you said, well, yeah, I think he's IPAF.

00:31:46.560 --> 00:31:51.378
So my next question was, you know, when do we treat? this guy was short of

00:31:51.378 --> 00:31:51.800
breath.

00:31:52.240 --> 00:31:55.120
I haven't given the PFTs because who knows what they are.

00:31:55.120 --> 00:31:57.160
We we, you know,
they're ordered kind of thing.

00:31:57.320 --> 00:31:58.320
We know the CT.

00:31:58.480 --> 00:32:02.320
So I guess helping us when, how much do we order?

00:32:02.320 --> 00:32:04.960
What do you guys order and when do we trigger treatment?

00:32:05.840 --> 00:32:07.600
Daniel, that's a loaded question.

00:32:08.480 --> 00:32:12.496
Yeah, I, I think I'll,
I'll say maybe a couple of words on,

00:32:12.496 --> 00:32:15.040
on follow up of ILD in this slide.

00:32:15.040 --> 00:32:16.727
And then,
and then we'll get a little bit to

00:32:16.727 --> 00:32:18.752
treatment and,
and we'll kind of go a little bit back

00:32:18.752 --> 00:32:19.840
and forth between us I think.

00:32:19.840 --> 00:32:23.774
And I'll maybe leave you with a bit of an ILD physicians kind of

00:32:23.774 --> 00:32:27.146
approach to treatment or,
or my kind of general overview of how I

00:32:27.146 --> 00:32:27.760
think of it.

00:32:28.440 --> 00:32:33.433
But in terms of follow up and, and this is really in line with

00:32:33.433 --> 00:32:36.586
the recent ACR guidelines for SARD,

00:32:36.586 --> 00:32:39.872
which again,
most of our evidence and most of our

00:32:39.872 --> 00:32:42.960
thinking around IPAF is, is taken from CTD-ILD.

00:32:43.840 --> 00:32:47.131
But in,
in all ILD we always follow these three

00:32:47.131 --> 00:32:47.680
domains.

00:32:47.680 --> 00:32:53.446
We always follow clinical sympomatology,
what PFTs are doing and it's really FVC

00:32:53.446 --> 00:32:58.215
and DLCO. DLCO I should mention and this may be helpful is that,

00:32:58.215 --> 00:33:00.280
but it can be quite variable.

00:33:00.840 --> 00:33:05.480
It can vary by as much as 10 to 15% predicted from visit to visit.

00:33:05.680 --> 00:33:10.080
So it's one of those where if you go from 70 to 60, I don't know, do I believe it?

00:33:10.080 --> 00:33:11.200
Do I just repeat it?

00:33:11.200 --> 00:33:11.920
Is that true?

00:33:11.920 --> 00:33:13.040
Are we worsening? I'm not sure.

00:33:13.360 --> 00:33:15.520
FVC should be a lot more reliable.

00:33:15.520 --> 00:33:18.424
And usually if you have a worsening of 5% or greater,

00:33:18.424 --> 00:33:20.200
I'll take that into account.

00:33:20.480 --> 00:33:22.880
And then the third thing is,
is always imaging.

00:33:23.200 --> 00:33:26.440
And so usually I think of things as like kind of two out of three.

00:33:26.600 --> 00:33:29.923
If two out of the three of these things are are getting worse over time,

00:33:29.923 --> 00:33:32.200
then I'm worried about something truly worsening.

00:33:33.080 --> 00:33:37.189
And the frequency of follow up, again, all of this is variable and it's based a

00:33:37.189 --> 00:33:38.320
little bit on gestalt.

00:33:38.320 --> 00:33:41.497
But at the beginning,
when I'm first seeing a patient like this,

00:33:41.497 --> 00:33:44.480
I'll think about following things every three to six months.

00:33:44.480 --> 00:33:48.941
And once they either get on treatment or their trajectory is a little bit more

00:33:48.941 --> 00:33:53.239
defined with a couple of data points, then we're a little bit more comfortable

00:33:53.239 --> 00:33:54.600
usually spacing that out.

00:33:56.360 --> 00:33:56.560
Yeah.

00:33:56.600 --> 00:33:57.120
Excellent.

00:33:57.120 --> 00:34:03.480
And by imaging, are you HRCTing, ultrasounding, plain chest X-ray?

00:34:03.600 --> 00:34:05.480
What are you doing usually?

00:34:05.960 --> 00:34:10.783
Yeah, I, I'd say 99.9% of the time it's gonna be an HRCT, a lot

00:34:10.783 --> 00:34:14.764
of the time at the especially at the beginning for

00:34:14.764 --> 00:34:18.440
things that are on the autoimmune spectrum.

00:34:18.920 --> 00:34:23.228
I would do both an inspiratory and expiratory view again to highlight the

00:34:23.228 --> 00:34:27.885
fact that that airway centric pattern
that we've kind of better defined in 2021

00:34:27.885 --> 00:34:32.427
and are starting to see more and more that this is actually what's showing up

00:34:32.427 --> 00:34:35.280
in these autoimmune flavored patients.

00:34:38.800 --> 00:34:41.800
So again, yes, what do, what do we do?

00:34:41.800 --> 00:34:44.881
So you know,
our question again to you was we,

00:34:44.881 --> 00:34:46.520
we don't think he has RA.

00:34:46.640 --> 00:34:51.151
So we don't think we should treat him as RA because we know how to treat RA,

00:34:51.151 --> 00:34:55.662
but we don't know how to treat ILD that might not be RA and we don't want to

00:34:55.662 --> 00:34:58.240
overtreat, but we don't want to undertreat.

00:34:58.400 --> 00:35:02.938
So we would have asked you, you know, do you want us to start something or do

00:35:02.938 --> 00:35:04.160
you want to start it?

00:35:04.400 --> 00:35:08.914
Do we think that we would go for MMF because he doesn't have inflammatory

00:35:08.914 --> 00:35:13.612
arthritis, Inflammatory arthritis,
MMF doesn't work very well for rheumatoid

00:35:13.612 --> 00:35:14.040
at all.

00:35:14.760 --> 00:35:18.288
So if he had new onset rheumatoid, we'd probably say, well,

00:35:18.288 --> 00:35:23.052
we're going to give this guy methotrexate and then rapidly move on if he doesn't

00:35:23.052 --> 00:35:25.640
respond well from his lungs and his joints.

00:35:25.880 --> 00:35:29.070
But if he was our IPAF, we'd probably say,

00:35:29.070 --> 00:35:32.840
do you want us to use MMF or do you want to use it?

00:35:33.080 --> 00:35:35.400
Do you guys want Septra or not?

00:35:35.400 --> 00:35:36.960
So we'd ask some of those questions.

00:35:37.120 --> 00:35:38.720
We would avoid Prednisone.

00:35:38.720 --> 00:35:40.480
So would you avoid Prednisone?

00:35:41.880 --> 00:35:42.760
I think so.

00:35:42.760 --> 00:35:45.440
In most cases you can try to avoid Prednisone.

00:35:45.440 --> 00:35:49.404
But the times when,
when we think about it more is when

00:35:49.404 --> 00:35:53.440
there's really that OP kind of consolidative look to it.

00:35:53.440 --> 00:35:56.716
And again,
things like lots of ground glass or lots

00:35:56.716 --> 00:36:01.567
of consolidation on the scan that we tend to think of that either rightly or

00:36:01.567 --> 00:36:04.654
wrongly,
in some cases that that's a lot of kind

00:36:04.654 --> 00:36:06.040
of acute inflammation.

00:36:06.280 --> 00:36:11.135
And so we think about taking the fire extinguisher to it in cases where there's

00:36:11.135 --> 00:36:15.081
a little bit less of that or it's, it's essentially more on the,

00:36:15.081 --> 00:36:16.720
on the mild side of things.

00:36:17.440 --> 00:36:19.766
I think we have enough time to be able to

00:36:19.766 --> 00:36:23.800
wait for something like mycophenolate or azathioprine to, to kind of kick in.

00:36:24.520 --> 00:36:26.720
And so that's where I would usually start.

00:36:26.800 --> 00:36:30.188
I think in this case,
if you really wanted to consider by just

00:36:30.188 --> 00:36:34.039
based on the appearance of the CT, if you wanted to consider just a little

00:36:34.039 --> 00:36:38.352
bit of Prednisone for a couple of months, like kind of 10 to 20 milligrams and then

00:36:38.352 --> 00:36:42.203
slowly bring it down to help acutely if there's a, a problem with dyspnea,

00:36:42.203 --> 00:36:44.360
I think you, you would have reason for it.

00:36:44.360 --> 00:36:46.844
If dyspnea is really not the main presentation,

00:36:46.844 --> 00:36:51.037
I'd be very comfortable starting on mycophenolate and slowly ramping that up

00:36:51.037 --> 00:36:53.729
and taking the three months to get there,

00:36:53.729 --> 00:36:54.040
Right.

00:36:54.040 --> 00:36:55.840
And we wouldn't out from the room side.

00:36:55.840 --> 00:36:58.686
We wouldn't give Septra if they were like,
Bactrim/Septra

00:36:58.686 --> 00:37:01.760
if they were on low dose Prednisone or no pred.

00:37:01.760 --> 00:37:04.880
We just don't tend to high dose pred.

00:37:04.880 --> 00:37:08.373
We usually you guys want us to or you guys do it at it, it seems,

00:37:08.373 --> 00:37:10.120
which we're not doing in this guy.

00:37:10.480 --> 00:37:12.560
OK, so we can't follow these.

00:37:12.560 --> 00:37:14.120
So what do you think, Daniel?

00:37:14.120 --> 00:37:18.120
Do we kind of follow them even though it excludes by IPAF?

00:37:19.760 --> 00:37:23.800
It's a great question and it certainly does exclude IPAF.

00:37:23.800 --> 00:37:29.728
But I think in everything else in terms of the pragmatic and practical way we

00:37:29.728 --> 00:37:33.908
think of things,
we kind of as respirologists think of

00:37:33.908 --> 00:37:37.784
IPAF as CTD-ILD adjacent and we kind of treat it

00:37:37.784 --> 00:37:39.760
similarly if not the same.

00:37:39.760 --> 00:37:42.000
So I think it's fair to use this.

00:37:43.160 --> 00:37:43.320
Yeah.

00:37:43.480 --> 00:37:46.040
And then again,
you can see mycophenolate comes out.

00:37:46.160 --> 00:37:51.366
So a lot of the data are extrapolated from the Scleroderma trials to our other

00:37:51.366 --> 00:37:51.960
diseases.

00:37:52.120 --> 00:37:56.560
So I would not use in rheumatoid arthritis MMF if their joints are active.

00:37:56.560 --> 00:37:59.920
I might add it later,
but it it lacks face validity.

00:37:59.920 --> 00:38:04.706
We would go to rituximab if they had active joints on the CSD-MARD if they

00:38:04.706 --> 00:38:07.960
needed something to get the disease under control,

00:38:07.960 --> 00:38:10.960
both extra-parenchymal as well as parenchymal.

00:38:11.080 --> 00:38:14.554
But these are just little, you know, this is at least a guideline with,

00:38:14.554 --> 00:38:16.725
you know,
any extrapolation is going to have

00:38:16.725 --> 00:38:17.160
opinions.

00:38:17.400 --> 00:38:21.714
So, yeah,
so limited evidence and we kind of do

00:38:21.714 --> 00:38:25.040
what we think is right.

00:38:25.040 --> 00:38:29.454
And if they're not doing well enough,
this is where I think Rheum and Resp will

00:38:29.454 --> 00:38:32.640
talk again and say, "hey,
what do you think we should do?

00:38:32.800 --> 00:38:34.640
Do we add, do we switch?

00:38:35.280 --> 00:38:37.120
Do we get access to something?

00:38:37.280 --> 00:38:41.762
Is this progressive pulmonary fibrosis where maybe a drug like nintedanib

00:38:41.762 --> 00:38:42.840
would be indicated?"

00:38:43.080 --> 00:38:48.047
And can I ask Daniel,
and in your experience with IPAF from the

00:38:48.047 --> 00:38:52.245
big Canadian registry,
what proportion of IPAF do you think

00:38:52.245 --> 00:38:57.702
would be progressive pulmonary fibrosis enough to require an antifibrotic if

00:38:57.702 --> 00:39:02.880
there was no access issue and no cost issue etcetera, no tolerance issue.

00:39:04.040 --> 00:39:09.629
I think we get to reach about to the to the point of of reaching about 1/2,

00:39:09.629 --> 00:39:14.335
maybe not quite a half,
but but somewhere between between about

00:39:14.335 --> 00:39:20.440
1/3 and and 1/2 of individuals that that will be progressive in this group, right.

00:39:20.440 --> 00:39:23.816
And that's about,
I think what our experience would be on

00:39:23.816 --> 00:39:27.600
some of the other diseases where we don't really have much data.

00:39:28.720 --> 00:39:33.911
So I think that that's helpful and just again to remind the audience,

00:39:33.911 --> 00:39:39.400
we prefer if we're going to use,
I'll call it stronger therapies and MMF.

00:39:39.400 --> 00:39:44.238
So sort of second line therapies occasionally first line in a certain

00:39:44.238 --> 00:39:48.040
patient population,
rituximab versus cyclophosphamide.

00:39:48.040 --> 00:39:51.680
So rituximab was about equal, but it was safer.

00:39:51.760 --> 00:39:57.959
So cyclophosphamide
it's not out of fashion because of it's

00:39:57.959 --> 00:39:59.600
not as beneficial.

00:39:59.720 --> 00:40:03.900
It's really safety and it's risk of infection in particular that we worry

00:40:03.900 --> 00:40:06.160
about and you can see there's different

00:40:06.240 --> 00:40:07.600
ways the drugs behave.

00:40:07.600 --> 00:40:12.460
But in the Scleroderma subgroup, by the way, most had failed MMF,

00:40:12.460 --> 00:40:17.909
whereas in the other groups most were unexperienced of any sort of immune

00:40:17.909 --> 00:40:18.720
modulation.

00:40:18.880 --> 00:40:23.114
So you can see they're pretty similar on how they're responding in the different

00:40:23.114 --> 00:40:23.480
groups.

00:40:23.720 --> 00:40:29.687
And our European league that does Scleroderma,

00:40:29.687 --> 00:40:31.200
it's called EUSTAR.

00:40:31.400 --> 00:40:33.713
They looked at drugs, this is now Scleroderma,

00:40:33.713 --> 00:40:37.160
but it's ILD and saying I don't know anything kind of works the same.

00:40:37.160 --> 00:40:39.560
So they didn't have any obvious winner.

00:40:39.920 --> 00:40:43.400
And in my opinion,
even though the guy doesn't have RA with

00:40:43.400 --> 00:40:46.474
that RF positive,
I mean we'll keep following him or

00:40:46.474 --> 00:40:50.650
helping to Co-manage as as needed depending on the team that is looking

00:40:50.650 --> 00:40:51.520
after this guy.

00:40:51.520 --> 00:40:58.960
But in general most of our drugs that we use in treating RA are lung friendly.

00:40:59.160 --> 00:41:02.720
Leflunomide might not be but that's my opinion based on

00:41:02.720 --> 00:41:07.492
It was only ever used when people did worse and failed drugs before we had the

00:41:07.492 --> 00:41:08.120
biologics.

00:41:08.120 --> 00:41:12.080
So it might have gotten a bad rep because worse people got the drugs for a while.

00:41:12.080 --> 00:41:17.111
TNF had a bad rep because there was more ILD in Japan when the TNF first came out

00:41:17.111 --> 00:41:17.480
in RA.

00:41:18.520 --> 00:41:21.400
But again,
the worst patients have high disease

00:41:21.400 --> 00:41:24.760
activity for a long time,
so now it's on the good side.

00:41:24.760 --> 00:41:27.920
So I had to like, you know, jump over and put a TNF.

00:41:27.920 --> 00:41:29.040
So I still did a question mark.

00:41:29.040 --> 00:41:33.358
But there's data from the VA where it's mostly men and a lot of them smoke with

00:41:33.358 --> 00:41:33.520
RA.

00:41:33.960 --> 00:41:38.712
And basically TNF when you adjust for disease activity, etcetera,

00:41:38.712 --> 00:41:42.960
was as good or as bad on nuance at ILD as the other drugs.

00:41:43.800 --> 00:41:47.775
And our goals of treatment that I think are can I improve quality of life,

00:41:47.775 --> 00:41:50.320
prolonged survival,
change the Natural History?

00:41:50.320 --> 00:41:53.800
Can I reverse it, improve it, stabilize it or slow worsening

00:41:53.800 --> 00:41:58.583
So it really depends on their response and how much irreversibility there

00:41:58.583 --> 00:42:00.200
already is with fibrosis.

00:42:00.520 --> 00:42:03.400
Do I immune suppress,
give them an antifibrotic or both?

00:42:03.600 --> 00:42:05.480
Are they transplantable?

00:42:05.480 --> 00:42:07.760
And that's a long wait and they might die on the list.

00:42:07.760 --> 00:42:08.600
So I want to get them.

00:42:08.840 --> 00:42:11.990
I want to ask my respirology colleagues early-ish, "Hey,

00:42:11.990 --> 00:42:16.658
would this guy be consider for transplant if AB and C don't happen because then we

00:42:16.658 --> 00:42:20.990
can start getting a bunch of tests in order" and obviously all the adjunctive

00:42:20.990 --> 00:42:21.440
therapy.

00:42:21.640 --> 00:42:23.640
Now, Daniel, because I did this slide.

00:42:23.640 --> 00:42:27.909
Is there am I missing something in this exercising them for sure smoking

00:42:27.909 --> 00:42:30.600
cessation for sure oxygen if they're hypoxic.

00:42:30.800 --> 00:42:33.120
But am I missing something major, do you think?

00:42:33.920 --> 00:42:35.360
No, I love all of this, though.

00:42:35.400 --> 00:42:39.559
The one other thing that I will sometimes, because a lot of the patients that that

00:42:39.559 --> 00:42:42.515
we see always like to know what can I do to help and what,

00:42:42.515 --> 00:42:44.319
what can I do to make things better?

00:42:44.920 --> 00:42:47.400
And certainly exercise is,
is the biggest answer to that.

00:42:47.600 --> 00:42:50.836
The only other thing that I,
I think we're getting more and more

00:42:50.836 --> 00:42:54.120
evidence for now is trying to avoid air pollution as much as possible.

00:42:54.360 --> 00:42:56.768
And it's a nebulous and difficult thing to

00:42:56.768 --> 00:42:59.618
say, you know,
like spend your spend your day inside and,

00:42:59.618 --> 00:43:01.240
use a filter in your bedroom.

00:43:02.440 --> 00:43:06.270
But on days when, for example, especially in BC when there are big

00:43:06.270 --> 00:43:11.073
forest fires and you know, the, the PM 2.5, the particulate matter 2.5 microns is,

00:43:11.073 --> 00:43:12.560
is really high in the air.

00:43:12.720 --> 00:43:16.678
Those are probably good days if you can kind of stay at home with the windows

00:43:16.678 --> 00:43:18.760
shut, especially for people with bad ILD.

00:43:18.760 --> 00:43:20.280
I would recommend that for them.

00:43:20.720 --> 00:43:23.000
Yeah,
'cause you can certainly exacerbate it.

00:43:23.000 --> 00:43:26.560
That's any lung problem with the, the high pollutants.

00:43:27.440 --> 00:43:29.200
Totally want to talk about this one.

00:43:29.800 --> 00:43:30.840
Yeah, absolutely. 

00:43:30.880 --> 00:43:34.320
So I will say for the audience, Daniel, define AF.

00:43:34.320 --> 00:43:37.840
Because again, that's, it's a-fib, which we know it's not.

00:43:38.440 --> 00:43:39.880
Yeah, yeah, no problem.

00:43:39.920 --> 00:43:44.000
Just before I get to this,
I might just say I think methotrexate.

00:43:44.560 --> 00:43:48.097
I'll just say a few words about methotrexate because I often see this and

00:43:48.097 --> 00:43:50.440
there's often a lot of worry about methotrexate.

00:43:50.440 --> 00:43:53.130
And
I think a lot of the literature from the

00:43:53.130 --> 00:43:56.605
1980s is unfortunately a bit polluted with what we call

00:43:56.605 --> 00:44:00.080
what is acute pneumonitis related to methotrexate state.

00:44:00.360 --> 00:44:03.630
And so basically similar to what was a question in the,

00:44:03.630 --> 00:44:06.667
in the comments here about what we see for example,

00:44:06.667 --> 00:44:09.120
after giving people checkpoint inhibitors.

00:44:09.320 --> 00:44:13.362
So when we have this pneumonitis kind of just lung inflammation,

00:44:13.362 --> 00:44:18.400
a lot of the times we'll see this acute ground glass acute inflammatory picture.

00:44:19.120 --> 00:44:22.615
And that's not necessarily a chronic fibrosing ILD,

00:44:22.615 --> 00:44:27.925
the kind of chronic fibrosing ILD that I would classify as like a UIP picture,

00:44:27.925 --> 00:44:32.160
an NSIP picture over time is a little bit different from that.

00:44:32.160 --> 00:44:35.661
So with methotrexate,
I think you can have a couple of people

00:44:35.661 --> 00:44:40.236
who will react in an idiosyncratic manner and will just have inflammation in the

00:44:40.236 --> 00:44:43.400
lung, some, you know,
6 to 12 months after starting it.

00:44:43.680 --> 00:44:46.690
But does methotrexate really lead to, you know,

00:44:46.690 --> 00:44:51.520
a UIP pattern where you have chronic fibrosing disease over years and years?

00:44:51.760 --> 00:44:54.400
And I think the answer to that is more and more no.

00:44:54.400 --> 00:44:58.877
And, and in, in 2020, there was a great meta analysis from,

00:44:58.877 --> 00:45:01.080
from the author's name is Juge.

00:45:01.160 --> 00:45:06.516
It's a Juge that suggested that actually these people who are getting methotrexate

00:45:06.516 --> 00:45:09.484
with RA,
they actually present with their ILD

00:45:09.484 --> 00:45:12.840
later and,
and are less likely perhaps to have ILD.

00:45:13.680 --> 00:45:15.883
And so there might be some confounding

00:45:15.883 --> 00:45:19.439
with methotrexate that occurred throughout the 80s and the 90s and the
00:45:19.439 --> 00:45:19.640
70s.

00:45:20.280 --> 00:45:23.000
And yes,
is acute pneumonitis possible?

00:45:23.200 --> 00:45:23.680
Yes.

00:45:23.680 --> 00:45:26.691
But beyond that,
and especially for someone that's been on

00:45:26.691 --> 00:45:29.548
methotrexate for, you know, 2-3, four years and beyond,

00:45:29.548 --> 00:45:31.080
I don't really worry about it.

00:45:31.080 --> 00:45:33.451
So I'm, I'm, I've actually started, it's a,

00:45:33.451 --> 00:45:37.494
a bit of a sin for a respirologist,
but I've actually started people with,

00:45:37.494 --> 00:45:41.159
with RA-ILD on methotrexate to the, to the chagrin of my colleagues.

00:45:42.000 --> 00:45:46.830
But I think that's, that's probably where, where my thought process lies with

00:45:46.830 --> 00:45:51.909
methotrexate. In terms of I put this trial just because this is one of the biggest

00:45:51.909 --> 00:45:55.440
ones in our field and this is evidence for antifibrotic.

00:45:56.360 --> 00:45:59.304
And so
our two antifibrotics are nintedanib

00:45:59.304 --> 00:46:01.400
and the other is called pirfenidone.

00:46:01.400 --> 00:46:04.777
But nintedanib is probably the one that you'll see most because it has the

00:46:04.777 --> 00:46:05.600
strongest evidence.

00:46:06.360 --> 00:46:10.643
And before and since 2014,
we had been using it for idiopathic

00:46:10.643 --> 00:46:11.840
pulmonary fibrosis.

00:46:12.480 --> 00:46:16.246
And then in 2019,
we found out that if you take people who

00:46:16.246 --> 00:46:21.268
progress and we've defined progression by what you see in that little box up at the

00:46:21.268 --> 00:46:23.720
right, two out of three of these domains.

00:46:23.720 --> 00:46:26.464
Again,
we always look at the domains of clinical,

00:46:26.464 --> 00:46:28.200
pulmonary function and imaging.

00:46:28.200 --> 00:46:29.600
Those are three big ones.

00:46:30.120 --> 00:46:34.176
So worsening symptoms,
worsening physiology with either an FVC

00:46:34.176 --> 00:46:39.520
decline of 5% or more or DLCO decline of 10% or more and then worsening radiology.

00:46:39.520 --> 00:46:41.400
And that that's a pretty nebulous category.

00:46:41.400 --> 00:46:45.482
It can be worsening reticulation, worsening ground glass more,

00:46:45.482 --> 00:46:49.760
more of the lung that's already affected appearing more fibrotic.

00:46:50.240 --> 00:46:54.829
It's a little bit nebulously defined,
but two out of those three would qualify

00:46:54.829 --> 00:46:57.560
you for PPF or progressive pulmonary fibrosis.

00:46:57.560 --> 00:47:00.476
And if you take those people and you

00:47:00.476 --> 00:47:04.123
put half of them on nintedanib and half of them on placebo,

00:47:04.123 --> 00:47:09.106
you see the curves as you do here on the screen with a separation in terms of FVC

00:47:09.106 --> 00:47:10.200
decline over time.

00:47:10.400 --> 00:47:14.625
So those people who get nintedanib who have progressed are,

00:47:14.625 --> 00:47:19.272
are less likely they're,
they're worsening FVC is attenuated over 

00:47:19.272 --> 00:47:23.920
time compared to those people on placebo, the lower lighter line.

00:47:24.240 --> 00:47:28.332
And so based on this,
which was really a seminal trial in in

00:47:28.332 --> 00:47:31.368
the field,
we've now kind of defined this new

00:47:31.368 --> 00:47:36.054
phenotype of people who are progressive regardless of their diagnosis,

00:47:36.054 --> 00:47:41.598
regardless if they have CTD-ILD or if they have IPAF or if they have idiopathic NSIP

00:47:41.598 --> 00:47:44.040
or if they have sarcoid, for example.

00:47:44.400 --> 00:47:47.454
So regardless of that diagnostic label, if they've progressed,

00:47:47.454 --> 00:47:49.200
they would kind of qualify for this.

00:47:49.200 --> 00:47:52.120
And on this basis,
we give people nintedanib these days.

00:47:54.440 --> 00:48:01.648
So looking at there was a guideline for this that came out and should be on the

00:48:01.648 --> 00:48:02.640
next slide.

00:48:02.640 --> 00:48:02.880
Yeah.

00:48:03.320 --> 00:48:09.320
So based on this trial,
a guideline came out in 2022 in ILD.

00:48:09.520 --> 00:48:13.130
And this just shows you kind of with the shaded blue area,

00:48:13.130 --> 00:48:17.842
the percentage of patients with these diagnostic labels that we might expect

00:48:17.842 --> 00:48:18.760
would progress.

00:48:18.760 --> 00:48:24.183
And you see in in CTD-ILD that about half of RA and half of systemic sclerosis,

00:48:24.183 --> 00:48:27.960
half of these individuals will qualify for this label.

00:48:27.960 --> 00:48:31.902
And as I've said before,
when looking at a real world study in

00:48:31.902 --> 00:48:34.649
the Canadian registry for pulmonary fibrosis,

00:48:34.649 --> 00:48:36.800
it checks out that it is about half.

00:48:36.800 --> 00:48:42.680
I think the actual number for IPAF specifically is 55%.

00:48:43.240 --> 00:48:46.280
So a fair number of them will progress. 

000:48:49.440 --> 00:48:54.561
And so now we have immunosuppression, we have antifibrotics,

00:48:54.561 --> 00:48:57.080
which is it and in what order?

00:48:57.440 --> 00:49:02.008
And hopefully I can give you a little bit leave you with a bit of a flow chart just

00:49:02.008 --> 00:49:05.000
to highlight kind of the thinking that goes into this.

00:49:05.280 --> 00:49:08.318
And as I've always said,
we we largely extrapolate from the

00:49:08.318 --> 00:49:12.217
connective tissue disease literature, which generally relies first on immune

00:49:12.217 --> 00:49:14.040
suppression as a first line therapy.

00:49:14.640 --> 00:49:18.320
And then I throw out three additional points on top of this.

00:49:18.960 --> 00:49:21.760
You got to take into account extra pulmonary manifestations.

00:49:22.480 --> 00:49:26.835
You have to 1st qualify for PPF from a pragmatic standpoint to get the

00:49:26.835 --> 00:49:31.805
government to pay for your anti fibrotic for an intentative, which is about $40,

00:49:31.805 --> 00:49:32.480
000 a year.

00:49:33.320 --> 00:49:39.042
And then the third thing and more and
more we rely on what the morphology looks

00:49:39.042 --> 00:49:39.400
like.

00:49:39.520 --> 00:49:40.960
What kind of pattern is there?

00:49:40.960 --> 00:49:45.120
Is it more inflammatory looking or more fibrotic looking to help us?

00:49:45.400 --> 00:49:48.687
Again, rightly or wrongly, there's, there's not much evidence for this,

00:49:48.687 --> 00:49:50.240
but this is our, our best gestalt.

00:49:50.240 --> 00:49:52.484
So we use what that pattern might look like,

00:49:52.484 --> 00:49:56.325
what those features look like to decide whether we're gonna go stronger down

00:49:56.325 --> 00:49:58.520
immunosuppression or antifibrotics or both.

00:49:59.240 --> 00:50:02.560
And so I've made a little, little flow chart here.

00:50:02.560 --> 00:50:04.880
So you have someone that you wanna call IPAF.

00:50:05.560 --> 00:50:08.861
The first thing that I'd consider is whether there are extra pulmonary

00:50:08.861 --> 00:50:12.489
symptoms that need immunosuppression and then kind of start from there as my,

00:50:12.489 --> 00:50:13.280
as my groundwork.

00:50:13.280 --> 00:50:16.146
So, and that's really our, our rheumatologist who,

00:50:16.146 --> 00:50:17.720
who helped me out with that.

00:50:18.040 --> 00:50:22.384
And then the next question is,
is there a significant burden of ILD and

00:50:22.384 --> 00:50:27.272
if there is a significant burden of ILD, usually most of the time we would think

00:50:27.272 --> 00:50:32.039
about immunosuppression similar to a CTD- ILD and whether that's a little bit of

00:50:32.039 --> 00:50:35.600
Prednisone and usually more often a steroid sparing agent.

00:50:36.400 --> 00:50:39.280
That's what we would start and then follow up and see how things go.

00:50:39.640 --> 00:50:44.418
There is kind of a little bit of an exception to this where if there's a

00:50:44.418 --> 00:50:47.494
significant burden of ILD and that morphology,

00:50:47.494 --> 00:50:49.719
the look of it really is fibrotic.

00:50:49.720 --> 00:50:55.701
It really has a lot of honeycombing and reticulation or UIP as opposed to NSIP or

00:50:55.701 --> 00:50:55.920
OP.

00:50:57.200 --> 00:51:01.533
And there's already enough follow up data that they meet progressive pulmonary

00:51:01.533 --> 00:51:05.373
fibrosis criteria so that they're eligible from the government for

00:51:05.373 --> 00:51:09.926
nintedanib and they don't need any more immunosuppression from an extra pulmonary

00:51:09.926 --> 00:51:12.668
perspective in that kind of fairly select sliver,

00:51:12.668 --> 00:51:16.837
which often ends up being rheumatoid arthritis patients with a UIP pattern,

00:51:16.837 --> 00:51:17.880
to be quite honest.

00:51:18.160 --> 00:51:22.130
And those people I might off the bat consider an antifibrotic right then and

00:51:22.130 --> 00:51:22.440
there.

00:51:23.280 --> 00:51:26.795
And then part you go down to the same algorithm of let's follow up,

00:51:26.795 --> 00:51:29.742
let's look at those kind of three domains, the clinical,

00:51:29.742 --> 00:51:33.000
their pulmonary tests and their imaging and see how things go.

00:51:33.280 --> 00:51:34.480
If they're stable, great.

00:51:34.840 --> 00:51:37.640
If not,
then we we go back to the drawing board.

00:51:38.040 --> 00:51:40.731
If they're not stable, essentially by definition,

00:51:40.731 --> 00:51:44.337
by exclusion you get into what, what would qualify for progressive

00:51:44.337 --> 00:51:45.360
pulmonary fibrosis.

00:51:45.640 --> 00:51:47.920
And at that point,
all options are open to you.

00:51:48.280 --> 00:51:51.780
And at that point,
I would use predominantly the way that

00:51:51.780 --> 00:51:55.280
things look like on the CT to think about what I do next.

00:51:55.520 --> 00:51:59.338
If it really still looks really inflammatory as it's progressed with a

00:51:59.338 --> 00:52:03.640
lot of ground glass and consolidation,
we'd think about more immunosuppression.

00:52:03.640 --> 00:52:08.502
And that's when we
beg you guys to help us with a biologic,

00:52:08.502 --> 00:52:11.040
for example, like rituximab or toci.

00:52:11.840 --> 00:52:15.825
And if it really looks more fibrotic at that point or we've already maxed out

00:52:15.825 --> 00:52:18.891
immunosuppression,
they're already on MMF and rituximab and

00:52:18.891 --> 00:52:20.680
they're, they're still progressing.

00:52:20.680 --> 00:52:22.760
And it's a 50 year old woman with
scleroderma.

00:52:23.040 --> 00:52:26.385
Then you think about adding on an antifibrotic,

00:52:26.385 --> 00:52:31.822
adding on nintedanib and we kind of go through this algorithm until we max out

00:52:31.822 --> 00:52:34.680
both immunosuppression and antifibrotics.

00:52:35.320 --> 00:52:39.928
And at that point you think about supplemental oxygen, lung transplant and

00:52:39.928 --> 00:52:40.800
or palliation.

00:52:41.360 --> 00:52:45.745
But this really just goes to show that we are thinking more and more of the

00:52:45.745 --> 00:52:49.034
features of whether they look inflammatory, fibrotic to,

00:52:49.034 --> 00:52:51.400
to help guide us what we want to do next.

00:52:52.240 --> 00:52:54.640
And I think, I'm sorry to interrupt.

00:52:54.640 --> 00:52:57.520
I just want to mention that we're having 5 minutes left.

00:52:57.520 --> 00:53:01.625
It's 8:55,
but I think we've answered the question

00:53:01.625 --> 00:53:04.040
through the, the presentation.

00:53:04.040 --> 00:53:07.168
So I think we can continue,
but just keep in mind there's 5 minutes

00:53:07.168 --> 00:53:07.720
left, right.

00:53:07.960 --> 00:53:10.280
And this, this we can do quickly.

00:53:10.280 --> 00:53:15.649
So Daniel, you wanna tell us,
'cause you're referring this patient to

00:53:15.649 --> 00:53:15.880
us?

00:53:16.160 --> 00:53:17.200
Yeah, Yeah.

00:53:17.200 --> 00:53:21.443
So and and we see this often,
we see often individuals who are are

00:53:21.443 --> 00:53:26.700
referred to us with abnormal imaging and then they come into clinic and we hum and

00:53:26.700 --> 00:53:31.640
How about whether there could be an autoimmune condition that's driving this.

00:53:31.640 --> 00:53:35.473
And especially as I said, not to the exclusion of other

00:53:35.473 --> 00:53:38.731
patterns,
but especially when we see an NSIP or

00:53:38.731 --> 00:53:43.970
an organizing pneumonia type of pattern that again gets our spidey senses up more
00:53:43.970 --> 00:53:45.439
for autoimmune disease.

00:53:45.640 --> 00:53:48.878
And especially when we also have a hodgepodge of,

00:53:48.878 --> 00:53:53.476
of mildly positive autoimmune serologies, we rely very heavily on,

00:53:53.476 --> 00:53:57.879
on our rheumatologist to,
to help try to make sense of that, right.

00:53:57.880 --> 00:53:59.942
And when we see some mechanics, hands look,

00:53:59.942 --> 00:54:02.520
think of people holding their wrenches and everything.

00:54:02.720 --> 00:54:09.288
So it's often skin that looks like it's a bunch of lines of almost like dermatitis

00:54:09.288 --> 00:54:10.080
or eczema.

00:54:10.320 --> 00:54:15.280
But it's on the radial side of fingers especially #2 so that can be your clue.

00:54:15.280 --> 00:54:18.000
It's usually not on the owner side of fingers.

00:54:19.080 --> 00:54:21.800
So the myositis panel, there's a lot there.

00:54:21.800 --> 00:54:24.720
And this I got off of like Google and stuff.

00:54:24.720 --> 00:54:29.112
But these synthetases,
so the old and the old days,

00:54:29.112 --> 00:54:34.519
we only had Jo-1,
but the other synthetases, so our PL-7, PL-12,

00:54:34.519 --> 00:54:35.280
etcetera.

00:54:35.560 --> 00:54:39.107
Then we know the MDA 5, everybody on the call knows that they

00:54:39.107 --> 00:54:43.627
scare us with their ILD and we have to treat them pretty aggressively from the

00:54:43.627 --> 00:54:44.200
beginning.

00:54:44.680 --> 00:54:47.560
We think not everyone, but almost all MDA-5s.

00:54:47.560 --> 00:54:51.385
They used to have a high mortality, but they'd often present their myositis

00:54:51.385 --> 00:54:54.960
in the ICU because their lungs were going, you know, south pretty quickly.

00:54:55.240 --> 00:55:01.000
So then the TIF-1 and the NXP2, they're associated with malignancy.

00:55:01.680 --> 00:55:04.600
1 can be associated more as well with calcinosis.

00:55:05.200 --> 00:55:08.520
So the problem is there's so many of them and we don't even know what they mean.

00:55:08.520 --> 00:55:11.720
And not all myositis panels have them all and they keep discovering more.
fdfbc5d9-648e-47d2-84b6-023281eaaafa-0 00:55:12.000 --> 00:55:14.040
But that's where you might ask us.

00:55:14.040 --> 00:55:18.044
And we try to say, well,
the myositis panel and the ENA panel,

00:55:18.044 --> 00:55:19.240
we're both positive.

00:55:19.240 --> 00:55:22.560
But when they looked at antibodies, they were all negative.

00:55:22.680 --> 00:55:26.040
So it's either a low, a low positive of something,

00:55:26.040 --> 00:55:29.820
or it's just there's some,
there's just a lot of autoimmunity,

00:55:29.820 --> 00:55:31.080
nonspecific going on.

00:55:31.080 --> 00:55:35.800
Like say if the person had an RF or something as well, which this one didn't.

00:55:36.000 --> 00:55:38.800
So the question is, do they have a CTD?

00:55:38.800 --> 00:55:40.440
We'd probably say no.

00:55:40.920 --> 00:55:42.440
What do we treat with ILD?

00:55:42.440 --> 00:55:44.080
You've gone through the algorithm. 

00:55:44.320 --> 00:55:46.800
Should antibodies be redone because there's borderline?

00:55:46.800 --> 00:55:49.280
Sometimes resps will ask us and we say no.

00:55:50.320 --> 00:55:53.840
So what about do we worry about PAH?

00:55:54.480 --> 00:55:59.550
Because maybe they're kind of myositis like- ish with some antibodies that are,

00:55:59.550 --> 00:56:02.438
you know,
not yet detected or a low level of

00:56:02.438 --> 00:56:03.080
something.

00:56:03.280 --> 00:56:07.880
And if they have, we run into problems.

00:56:07.880 --> 00:56:09.915
And you,
you can pick the one you want to answer,

00:56:09.915 --> 00:56:10.200
Daniel.

00:56:10.200 --> 00:56:14.817
But if you don't want to pick this,
this question is what if they have NSIP

00:56:14.817 --> 00:56:16.640
and real PAH like it's proven?

00:56:16.800 --> 00:56:24.160
Do we treat both or does the NSIP exclude the PAH ability to treat?

00:56:24.880 --> 00:56:28.240
So and you already talked that the pattern is strongly predictive.

00:56:28.240 --> 00:56:33.203
So maybe just to answer in the final couple minutes this what about if there's

00:56:33.203 --> 00:56:36.721
NSIP and PAH,
we'll say it's a myositis like a myositis

00:56:36.721 --> 00:56:39.800
spectrum or even a scleroderma spectrum patient.

00:56:40.040 --> 00:56:45.720
What do you tell us to do or what do we then get the PAH people to help us with?

00:56:46.600 --> 00:56:49.565
Yeah, I,
I think it's reasonable to get the PAH

00:56:49.565 --> 00:56:54.235
people involved and kind of treat, treat both I would say for kind of for

00:56:54.235 --> 00:56:59.031
pearls for PAH especially my spidey senses go up for that when the diffusing

00:56:59.031 --> 00:57:01.240
capacity is disproportionately low.

00:57:01.840 --> 00:57:08.238
So usually you'll see kind of your FVC be above maybe about 20-25 ish percent above

00:57:08.238 --> 00:57:09.000
your DLCO.

00:57:09.000 --> 00:57:14.036
So you'll often see a kind of
prototypical patient come in with an FVC

00:57:14.036 --> 00:57:16.520
of 75% and a DLCO of let's say 50%.

00:57:16.960 --> 00:57:21.353
If I see a patient with an FVC of 80% and

00:57:21.353 --> 00:57:29.185
a DLCO of 40% and no emphysema to explain that low DLCO, an isolated low DLCO is,

00:57:29.185 --> 00:57:32.720
is often makes me tingle for PAH.

00:57:32.720 --> 00:57:36.640
And I'll very quickly send them for an echocardiogram to get a sense of things.

00:57:36.640 --> 00:57:40.058
And if there's any confusion or any, any sign of PAH there,

00:57:40.058 --> 00:57:44.577
I'll send them to the PAH clinic and, and consider them for a right heart Catch

00:57:44.577 --> 00:57:46.199
and, and they go from there.

00:57:46.760 --> 00:57:51.117
But in a word,
if they have both something on the

00:57:51.117 --> 00:57:55.040
autoimmune spectrum and PAH, it's reasonable.

00:57:55.040 --> 00:57:58.160
And we often do treat both and treat both kind of separately.

00:57:58.160 --> 00:58:00.555
So the PAH people will gladly see this

00:58:00.555 --> 00:58:03.007
patient and will do a right heart cath and,

00:58:03.007 --> 00:58:05.960
and determine PAH and then start vasodilator therapy.

00:58:06.400 --> 00:58:10.565
And we at the same time will look at the kind of inflammatory NSIP pattern and

00:58:10.565 --> 00:58:12.200
think about immunosuppressants.

Learning objectives:

  • Understand the clinical manifestations of IPAF

  • Discuss treatment options for IPAF

  • Illustrate the importance of collaboration between respirologists and rheumatologists in managing patients with IPAF 

Program date: March 20, 2025

Speaker: Dr. Janet Pope, MD, MPH, FRCPC

Rheumatologist
Professor of Medicine and Member of the Division of Rheumatology
Western University
Schulich School of Medicine
 

Speaker: Dr. Daniel Marinescu, MD, FRCPC

Clinical Assistant Professor
Division of Respirology,
Faculty of Medicine
University of British Columbia

Moderator: Dr. Caroline Vo, MD 

Clinical Instructor 
Rheumatology 
Hôpital Charles Le Moyne (QC)

The presenters are solely responsible for developing the content of this presentation and maintaining scientific accuracy, objectivity, and balance. Any discussions of clinical practice or treatment represent the opinions of the presenter alone. This video is made available for attendees, registrants, and individuals requesting further information on this learning program.